References
- Vosburg SK, Haynes C, Besharat A, et al. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) system web monitoring program. Pharmacoepidemiol Drug Saf. 2017;26(9):1044–1052.
- MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther. 2000;88(2):163–185.
- Mezei L, Murinson BB. Pain education in North American medical schools. J. Pain. 2011;12(12):1199–1208.
- Wenghofer EF, Wilson L, Kahan M, et al. Survey of Ontario primary care physicians’ experiences with opioid prescribing. Can Fam Physician. 2011;57(3):324–332.
- Gupta A, Patton C, Diskina D, et al. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors. Pain Physician. 2011;14(4):383–389.
- Hwang CS, Turner LW, Kruszewski SP, et al. Primary care physicians’ knowledge and attitudes regarding prescription opioid abuse and diversion. Clin J Pain. 2016;32(4):279–284.
- Brown J, Setnik B, Lee K, et al. Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting. J Opioid Manag. 2011;7(6):467–483.
- Cheatle MD, Gallagher RM, O’Brien CP. Low risk of producing an opioid use disorder in primary care by prescribing opioids to prescreened patients with chronic noncancer pain. Pain Med 2018; 19(4):764-773.
- Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–2296.
- Hoffman J Patients in pain, and a doctor who must limit drugs. The New York Times, Newyork, Newyork. 2016 Mar 16.
- Keast SL, Owora A, Nesser N, et al. Evaluation of abuse-deterrent or tamper-resistant opioid formulations on overall health care expenditures in a state medicaid program. J Manag Care Spec Pharm. 2016;22(4):347–356.
- Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17(4):279–287.
- White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy. 2009;7(1):61–70.
- Shei A, Rice JB, Kirson NY, et al. Characteristics of high-cost patients diagnosed with opioid abuse. J Manag Care Spec Pharm. 2015;21(10):902–912.
- Barnes M CMS proposed rule defies White House policy on abuse-deterrent medications. 2015 [cited 2017 Apr 7]. Available from: http://thehill.com/blogs/congress-blog/healthcare/252972-cms-proposed-rule-defies-white-house-policy-on-abuse-deterrent
- Keast S, Nesser N, Farmer K. Strategies aimed at controlling misuse and abuse of opioid prescription medications in a state Medicaid program: a policymaker’s perspective. Am J Drug Alcohol Abuse. 2015;41(1):1–6.
- CMS. Centers for Medicare & Medicaid Services (CMS) opioid misuse strategy 2016. 2017 [cited 2017 Apr 7]. Available from: https://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/CMS-Opioid-Misuse-Strategy-2016.pdf
- CBSN. Drugmakers promote profitable, but unproven, opioid solution. 2016 [cited 2017 Mar 30]. Available from: http://www.cbsnews.com/news/opioid-epidemic-drugmakers-promote-profitable-but-unproven-solution/
- Califf RM, Woodcock J, Ostroff S, et al. Response to prescription opioid abuse. N Engl J Med. 2016;374(15):1480–1485.
- State Pain Policy Advocacy Network. Abuse deterrent formulations. State pain policy finder: legislation and regulation 2017 [cited 2017 Mar 30]. Available from: http://cqrcengage.com/painmanagement/abusedeterrent
- Center for Lawful Access and Abuse Deterrence. Status of abuse-deterrent opioid analgesics. 2017 [cited 2017 Mar 30]. Available from: http://claad.org/wp-content/uploads/2017/01/Status-of-Abuse-Deterrent-Opioid-Analgesics.pdf
- Wapner J How much money do drug companies pay the FDA? Works in Progress 2012 [cited 2017 Mar 31]. Available from: http://blogs.plos.org/workinprogress/2012/01/25/how-much-money-do-drug-companies-pay-the-fda/
- Food and Drug Administration. Abuse-deterrent opioid medications. FDA Facts 2017 [cited 2017 Mar 31]. Available from: https://www.fda.gov/newsevents/newsroom/factsheets/ucm514939.htm
- McGinty EE, Kennedy-Hendricks A, Baller J, et al. Criminal activity or treatable health condition? News media framing of opioid analgesic abuse in the United States, 1998-2012. Psychiatr Serv. 2016;67(4):405–411.
- Ray B, O’Donnell D, Kahre K. Police officer attitudes towards intranasal naloxone training. Drug Alcohol Depend. 2015;146:107–110.
- Rando J, Broering D, Olson JE, et al. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. Am J Emerg Med. 2015;33(9):1201–1204.
- Pappa A Prescribing and dispensing opioids in the emergency department. 2013 [cited 2017 Apr 7]. Available from: http://www.premiersafetyinstitute.org/wp-content/uploads/Prescribing-Dispensing-Opioids-ER-Hallam-Final.pdf
- Ouyang H Seeking painkillers in the emergency room. The New York Times, Newyork, Newyork. 2016 Mar 25.
- Pletcher MJ, Kertesz SG, Kohn MA, et al. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):70–78.
- Volkow N, McLellan T, Cotto J. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305:1299–1301.
- Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs. 2012;19(2):144–155.
- Inciardi JA, Surratt HL, Cicero TJ, et al. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med. 2009;10(3):537–548.
- Logan J, Liu Y, Paulozzi L, et al. Opioid prescribing in emergency departments: the prevalence of potentially inappropriate prescribing and misuse. Med Care. 2013;51(8):646–653.
- Beaudoin FL, Straube S, Lopez J, et al. Prescription opioid misuse among ED patients discharged with opioids. Am J Emerg Med. 2014;32(6):580–585.
- Inciardi JA, Surratt HL, Cicero TJ, et al. Prescription drugs purchased through the internet: who are the end users? Drug Alcohol Depend. 2010;110(1–2):21–29.
- Meyer R, Patel AM, Rattana SK, et al. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17(6):372–387.
- Carroll I, Angst M, Clark J. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med. 2004;29(6):576–591.
- Rapp S, Ready L, Nessly M. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain. 1995;61(2):195–201.
- Willman MW, Liss DB, Schwarz ES, et al. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol. 2017;55(2):81–87.
- Brodrick JE, Brodrick CK, Adinoff B. Legal regimes surrounding naloxone access: considerations for prescribers. Am J Drug Alcohol Abuse. 2016;42(2):117–128.
- Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons - United States, 2014. Morb Mortal Wkly Rep. 2015;64(23):631–635.
- Knowlton A, Weir BW, Hazzard F, et al. EMS runs for suspected opioid overdose: implications for surveillance and prevention. Prehosp Emerg Care. 2013;17(3):317–329.
- Massachusetts Department of Public Health. Number of confirmed unintentional/undetermined opioid-related overdose deaths by city/town, MA residents January 2012-December 2015. 2016 [cited 2017 Apr 9]. Available from: http://www.mass.gov/eohhs/docs/dph/quality/drugcontrol/county-level-pmp/overdose-deaths-by-city-town-august-2016.pdf
- Wolfson-Stofko B, Bennett AS, Elliott L, et al. Drug use in business bathrooms: an exploratory study of manager encounters in New York City. Int J Drug Policy. 2017;39:69–77.
- State Pain Policy Advocacy Network. State pain policy finder: legislation & regulation. Legislation & Regulations 2016[cited 2016 Dec 29]. Available from: http://cqrcengage.com/painmanagement/legislation
- To amend title XIX of the Social Security Act to exclude abuse-deterrent formulations of prescription drugs from the Medicaid additional rebate requirement for new formulations of prescription drugs, and for other purposes. Rep. Bilirakis GM, trans. 114th ed2016.
- Jennings K Christie vetoes abuse-deterrent drugs bill amid addiction treatment push. 2016 cited 2017 Apr 7]. Available from: http://www.politico.com/states/new-jersey/story/2016/01/christie-vetoes-abuse-deterrent-drugs-bill-amid-addiction-treatment-push-030209
- Scott DC Christie brings heartfelt approach to Trump’s opioid commission, but some controversy too. Politics 2017; [cited 2017 Apr 7]. Available from: https://www.statnews.com/2017/03/29/chris-christie-opioids-commission/
- Stop Tampering of Prescription Pills Act of 2015. Rep. Keating W, trans. 2335. 114th Congress ed2015.
- Soyka M, Strehle J, Rehm J, et al. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative Sample. Eur Addict Res. 2017;23(2):97–105.
- Examining Opioid Treatment Infrastructure Act of 2017. H.R. 994. 115 Congress ed2017.
- United Nations Office on Drugs and Crime. World Drug Report. 2015 [cited 2017 Apr 6]. Available from: http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
- Hedden S, Kennet J, Lipari R, et al. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. 2015 [cited 2017 Apr 6]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm
- Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.
- Kuehn B. Opioid prescriptions soar: increase in legitimate use as well as abuse. J Am Med Assoc. 2007;297:249–251.
- Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing. Clin Pharmacol Ther. 2016;100(3):275–286.
- Butler SF, Black R, Grimes Serrano JM, et al. Estimating attractiveness for abuse of a not-yet-marketed “abuse-deterrent” prescription opioid formulation. Pain Med. 2010;11(1):81–91.
- Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother. 2012;26(4):348–361.
- Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29.
- McCabe SE, Cranford JA, Boyd CJ, et al. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562–575.
- Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9.
- Carise D, Dugosh KL, McLellan AT, et al. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750–1756.
- Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13.
- Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205–217.
- Surratt H, Kurtz S, Cicero T. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
- Kerridge B, Saha T, Chou S, et al. Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Drug Alcohol Depend. 2015;156:47–56.
- Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27(9):808–816.
- Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–189.
- Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274–1282.
- Cicero TJ, Ellis MS. Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics. Pharmacoepidemiol Drug Saf. 2015;24(2):205–207.
- Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–248.
- Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175(6):978–987.
- McNaughton EC, Black RA, Weber SE, et al. Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse. Pain Med. 2015;16(1):131–140.
- Faulkner-Gurstein R. The social logic of naloxone: peer administration, harm reduction, and the transformation of social policy. Soc Sci Med. 2017;180:20–27.
- Hewlett L, Wermeling DP. Survey of naloxone legal status in opioid overdose prevention and treatment. J Opioid Manag. 2013;9(5):369–377.
- Jones JD, Campbell A, Metz VE, et al. No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addict Behav. 2017;71:104–106.
- Barry CL, Kennedy-Hendricks A, Gollust SE, et al. Understanding Americans’ views on opioid pain reliever abuse. Addiction. 2016;111(1):85–93.